Comparative Efficacy and Tolerability of Lurasidone versus Other Atypical Antipsychotics for the Treatment of Adolescent Schizophrenia: A Systematic Literature Review and Network Meta-Analysis

2018 ◽  
Author(s):  
Daisy Ng-Mak
Keyword(s):  
Literature Review ◽  
Systematic Literature Review ◽  
Atypical Antipsychotics ◽  
Meta Analysis ◽  
Comparative Efficacy

scholarly journals Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis

2019 ◽  
Vol 29 (9) ◽  
pp. 1195-1205
Author(s):  
Celso Arango ◽  
Daisy Ng-Mak ◽  
Elaine Finn ◽  
Aidan Byrne ◽  
Antony Loebel
Keyword(s):  
Weight Gain ◽  
Literature Review ◽  
Atypical Antipsychotic ◽  
Systematic Literature Review ◽  
Atypical Antipsychotics ◽  
Meta Analysis ◽  
Similar Efficacy ◽  
Binary Outcomes ◽  
Schizophrenia Spectrum Disorders ◽  
Credible Intervals

AbstractThis network meta-analysis assessed the efficacy and tolerability of lurasidone versus other oral atypical antipsychotic monotherapies in adolescent schizophrenia. A systematic literature review identified 13 randomized controlled trials of antipsychotics in adolescents with schizophrenia-spectrum disorders. A Bayesian network meta-analysis compared lurasidone to aripiprazole, asenapine, clozapine, olanzapine, paliperidone extended-release (ER), quetiapine, risperidone, and ziprasidone. Outcomes included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), weight gain, all-cause discontinuation, extrapyramidal symptoms (EPS), and akathisia. Results were reported as median differences for continuous outcomes and odds ratios (ORs) for binary outcomes, along with 95% credible intervals (95% CrI). Lurasidone was significantly more efficacious than placebo on the PANSS (− 7.95, 95% CrI − 11.76 to − 4.16) and CGI-S (− 0.44, 95% CrI − 0.67 to − 0.22) scores. Lurasidone was associated with similar weight gain to placebo and statistically significantly less weight gain versus olanzapine (− 3.62 kg, 95% CrI − 4.84 kg to − 2.41 kg), quetiapine (− 2.13 kg, 95% CrI − 3.20 kg to − 1.08 kg), risperidone (− 1.16 kg, 95% CrI − 2.14 kg to − 0.17 kg), asenapine (− 0.98 kg, 95% CrI − 1.71 kg to − 0.24 kg), and paliperidone ER (− 0.85 kg, 95% CrI − 1.57 kg to − 0.14 kg). The odds of all-cause discontinuation were significantly lower for lurasidone than aripiprazole (OR = 0.28, 95% CrI 0.10–0.76) and paliperidone ER (OR = 0.25, 95% CrI 0.08–0.81) and comparable to other antipsychotics. Rates of EPS and akathisia were similar for lurasidone and other atypical antipsychotics. In this network meta-analysis of atypical antipsychotics in adolescent schizophrenia, lurasidone was associated with similar efficacy, less weight gain, and lower risk of all-cause discontinuation compared to other oral atypical antipsychotics.

scholarly journals Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis

2018 ◽  
Vol 40 (3) ◽  
pp. 480-494.e23 ◽  
Author(s):  
Eric M. Maiese ◽  
Claire Ainsworth ◽  
Jean-Gabriel Le Moine ◽  
Outi Ahdesmäki ◽  
Judith Bell ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Meta Analysis ◽  
Comparative Efficacy ◽  
Previously Treated

Comparative efficacy of multiple myeloma therapies for treatment of first relapse: A systematic literature review and network meta-analysis.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 8042-8042 ◽  
Author(s):  
Eric M Maiese ◽  
Jean-Gabriel Le Moine ◽  
Claire Ainsworth ◽  
Outi Ahdesmäki ◽  
Emma Howe
Keyword(s):  
Multiple Myeloma ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Comparative Efficacy ◽  
Free Survival ◽  
New Therapies ◽  
Risk Of Progression ◽  
First Relapse

8042 Background: Treatment for multiple myeloma (MM) in the US has undergone significant advances, with several new therapies recently FDA approved for relapse/refractory MM (RRMM), including carfilzomib+lenalidomide+dex (KRd), carfilzomib+dex (Kd), daratumumab+lenalidomide+dex (DRd), daratumumab+bortezomib+dex (DVd), ixaxomib+lenalidomide+dex (IRd), and elotuzumab+lenalidomide+dex (ERd). These new therapies have shown improvements in clinical outcomes in randomized controlled trials (RCTs). However, with few head-to-head RCTs, there is little comparative evidence to determine the most effective treatment for specific patients. A systematic literature review (SLR) and network meta-analysis (NMA) was conducted to determine the comparative efficacy (progression free survival (PFS)) of MM therapies for treating first relapse. Methods: The SLR searched MEDLINE, Embase, and the Cochrane Library for RCTs investigating the efficacy of treatments for RRMM (to August 2016). NMA was conducted on the PFS hazard ratios (HR), where available in RCTs for patients with one prior line of treatment, using Bayesian fixed effects mixed treatment comparisons. Results: Data formed two evidence networks. Network 1: RCTs with Rd; Network 2: RCTs with Vd. Analyses found DRd and DVd had the highest probability of being the best treatment (0.96 and 0.89, respectively). Compared to other MM therapies, DRd and DVd had the lowest risk of progression or death (PFS HR <1.0) (Table 1). For example, compared to KRd, DRd had a 41% (PFS HR 0.59) reduced risk of progression or death. Conclusions: This analysis provides comparative evidence among treatments where head-to-head RCTs have not been conducted. For treating first relapse, compared to other MM treatments, this analysis found that DRd and DVd had the highest probability of providing the longest progression free survival. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document